COVID-19 Pharmaceutical Intermediates
During a public health emergency, such as COVID-19, the FDA can issue emergency use authorizations (EUAs) to make new medications and medical products available without full FDA approval. Today, many medications are available through an EUA to treat COVID-19, both inside and outside of the hospital.
Pharmaceutical intermediates are used in during manufacturing of bulk drugs as raw materials. These are the material produced during the synthesis of an active pharmaceutical ingredient (API). However, pharmaceutical and biotech companies can make use of these drug intermediates for the purposes of research and development (R&D).
|CAS No.||Purity||Product Name||Stock|
|741267-75-4||97%||3-Pyrrolidinepropanoic acid, α-[[(1,1-dimethylethoxy)carbonyl]amino]-2-oxo-, (αS,3S)-||500g|
|565456-77-1||97%||(1R,2S,5S)-6,6-DIMETHYL-3-AZA-BICYCLO[3.1.0]HEXANE-2-CARBOXYLIC ACID METHYL ESTER HYDROCHLORIDE||5kg|
If you need any of these intermediates, please contact us to get a quote at email@example.com.